Advanced search
Publication Cover
Future Cardiology Volume 6, 2010 - Issue 2
Submit an article Journal homepage
439
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Riociguat for Pulmonary Hypertension

Hossein-Ardeschir Ghofrania Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany Tel.: +49 641 994 2422 Fax: +49 641 994 [email protected]Correspondence[email protected]
,
Robert Voswinckelb Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse [email protected]
,
Henning Gallc Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany. [email protected]
,
Ralph Schermulyd Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany. [email protected]
,
Norbert Weissmanne Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany. [email protected]
,
Werner Seegerf Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany. [email protected]
&
Friedrich Grimmingerg Department of Internal Medicine Medical Clinic II/V University Hospital Giessen and Marburg GmbHKlinikstrasse 36Giessen35392Germany. [email protected]
 show all
Pages 155-166 | Published online: 15 Mar 2010

Bibliography

  • Gaine SP , RubinLJ: Primary pulmonary hypertension.Lancet, 352, 719–725 (1998).
  • Simonneau G , RobbinsIM, BeghettiMet al.: Updated clinical classification of pulmonary hypertension.J. Am. Coll. Cardiol., 54, S43–S54 (2009).
  • Galie N , HoeperMM, HumbertMet al.: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).Eur. Heart J., 30, 2493–2537 (2009).
  • Rich S , DantzkerDR, AyresSMet al.: Primary pulmonary hypertension. A national prospective study.Ann. Intern. Med., 107, 216–223 (1987).
  • Levine DJ : Diagnosis and management of pulmonary arterial hypertension: implications for respiratory care.Respir. Care, 51, 368–381 (2006).
  • Taichman DB , McGoonMD, HarhayMOet al.: Wide variation in clinicians‘ assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension.Mayo Clin. Proc., 84, 586–592 (2009).
  • Galie N , TorbickiA, BarstRet al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.Eur. Heart J., 25, 2243–2278 (2004).
  • Hegewald MJ , MarkewitzB, ElliottCG: Pulmonary hypertension: clinical manifestations, classification and diagnosis.Int. J. Clin. Pract., 61, 5–14 (2007).
  • Badesch DB , ChampionHCet al., Angel Gomez-Sanchez M : Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., 54, S55–S66 (2009).
  • Kovacs G , BergholdA, ScheidlS, OlschewskiH: Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review.Eur. Respir. J., 34, 888–894 (2009).
  • Barst RJ , McGoonM, TorbickiAet al.: Diagnosis and differential assessment of pulmonary arterial hypertension.J. Am. Coll. Cardiol., 43, 40S–47S (2004).
  • Humbert M , KhaltaevN, BousquetJ, SouzaR: Pulmonary hypertension: from an orphan disease to a public health problem.Chest, 132, 365–367 (2007).
  • D‘Alonzo GE , BarstRJ, AyresSMet al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.Ann. Intern. Med., 115, 343–349 (1991).
  • Humbert M : Improving survival in pulmonary arterial hypertension.Eur. Respir. J., 25, 218–220 (2005).
  • Lettieri CJ , ShorrAF, BarnettS, AhmadS, NathanSD: Incidence and related outcomes of pulmonary hypertension in idiopathic pulmonary fibrosis.Chest, 128, 217S (2005).
  • Tueller C , StrickerH, SoccalPet al.: Epidemiology of pulmonary hypertension: new data from the Swiss registry.Swiss Med. Wkly, 138, 379–384 (2008).
  • Humbert M , SitbonO, ChaouatAet al.: Pulmonary arterial hypertension in France: results from a national registry.Am. J. Respir. Crit. Care Med., 173, 1023–1030 (2006).
  • Peacock AJ , MurphyNF, McMurrayJJ, CaballeroL, StewartS: An epidemiological study of pulmonary arterial hypertension.Eur. Respir. J., 30, 104–109 (2007).
  • Humbert M , SitbonO, SimonneauG: Treatment of pulmonary arterial hypertension.N. Engl. J. Med., 351, 1425–1436 (2004).
  • McLaughlin VV , McGoonMD: Pulmonary arterial hypertension.Circulation, 114, 1417–1431 (2006).
  • Chin KM , RubinLJ: Pulmonary arterial hypertension.J. Am. Coll. Cardiol., 51, 1527–1538 (2008).
  • Hoeper MM , MayerE, SimonneauG, RubinLJ: Chronic thromboembolic pulmonary hypertension.Circulation, 113, 2011–2020 (2006).
  • Dartevelle P , FadelE, MussotSet al.: Chronic thromboembolic pulmonary hypertension.Eur. Respir. J., 23, 637–648 (2004).
  • Jamieson SW , KapelanskiDP, SakakibaraNet al.: Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.Ann. Thorac. Surg., 76, 1457–1462 (2003).
  • Naeije R , HuezS: Expert opinion on available options treating pulmonary arterial hypertension.Expert Opin. Pharmacother., 8, 2247–2265 (2007).
  • Ghofrani HA , WilkinsMW, RichS: Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.Circulation, 118, 1195–1201 (2008).
  • Keogh AM , McNeilKD, WlodarczykJ, GabbayE, WilliamsTJ: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.J. Heart Lung Transplant., 26, 181–187 (2007).
  • Ghofrani HA , OsterlohIH, GrimmingerF: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.Nat. Rev. Drug Discov., 5, 689–702 (2006).
  • Galie N , GhofraniHA, TorbickiAet al.: Sildenafil citrate therapy for pulmonary arterial hypertension.N. Engl. J. Med., 353, 2148–2157 (2005).
  • Ghofrani HA , WiedemannR, RoseFet al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.Lancet, 360, 895–900 (2002).
  • Bhatia S , FrantzRP, SeversonCJ, DurstLA, McGoonMD: Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.Mayo Clin. Proc., 78, 1207–1213 (2003).
  • Chockalingam A , GnanaveluG, VenkatesanSet al.: Efficacy and optimal dose of sildenafil in primary pulmonary hypertension.Int. J. Cardiol., 99, 91–95 (2005).
  • Atz AM , AdatiaI, WesselDL: Rebound pulmonary hypertension after inhalation of nitric oxide.Ann. Thorac. Surg., 62, 1759–1764 (1996).
  • Evgenov OV , PacherP, SchmidtPM, HaskoG, SchmidtHH, StaschJP: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.Nat. Rev. Drug Discov., 5, 755–768 (2006).
  • Arnold WP , MittalCK, KatsukiS, MuradF: Nitric oxide activates guanylate cyclase and increases guanosine 3‘:5‘-cyclic monophosphate levels in various tissue preparations.Proc. Natl Acad. Sci. USA, 74, 3203–3207 (1977).
  • Ignarro LJ , BugaGM, WoodKS, ByrnsRE, ChaudhuriG: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.Proc. Natl Acad. Sci. USA, 84, 9265–9269 (1987).
  • Schermuly R , StaschJP, PullamsettiSSet al.: Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.Eur. Respir. J., 32, 881–891 (2008).
  • Ghofrani A , GrimmingerF: Modulating cGMP to treat lung diseases. In: cGMP: Generators, Effectors And Therapeutic Implications. Schmidt HHHW, Hofmann F, Stasch JP (Eds). Berlin Heidelberg: Springer-Verlag, Berlin, Germany 469–483 (2009).
  • Frey R , MückW, UngerS, Artmeier-BrandtU, WeimannG, WensingG: Single-dose pharmacokinetics, tolerability and safety of the soluble guanylate cyclase stimulator BAY 63–2521; an ascending-dose study in healthy male volunteers.J. Clin. Pharmacol., 48, 926–934 (2008).
  • Mittendorf J , WeigandS, Alonso-AlijaCet al.: Discovery of riociguat (BAY 63–2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.ChemMedChem, 4, 853–865 (2009).
  • Grimminger F , WeimannG, FreyRet al.: First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.Eur. Respir. J., 33, 785–792 (2009).
  • Ghofrani HA , HoeperMM, HoeffkenG, HalankM, WeimannG, GrimmingerF: Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH).Am. J. Respir. Crit. Care Med., 179, A3337 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.